Form 4: Candel Therapeutics Director Aguilar-Cordova Reduces Stake in CADL

Director Estuardo Aguilar-Cordova reports the sale of Candel Therapeutics shares held directly and indirectly through trusts.

Summary

• On February 21, 2025, Estuardo Aguilar-Cordova, a director of Candel Therapeutics, Inc. (CADL), reported the disposition of shares.
• He disposed of 10,582 shares held indirectly through the LKA 2022 Revocable Trust and 10,583 shares held directly.
• The transactions were executed at a price of $12.02 per share.
• Following these transactions, Aguilar-Cordova directly owns 162,929 shares and indirectly owns 120,861 shares through the LKA 2022 Revocable Trust, 2,013,100 shares through the Laura K. Aguilar 2020 Irrevocable Trust and 2,074,942 shares through the Estuardo Aguilar-Cordova 2020 Irrevocable Trust.
• He also holds 60,000 shares jointly with his spouse.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the insider selling shares, which can create uncertainty among investors. However, the magnitude of the sale is not substantial relative to the overall holdings.

Negatives

• A director has reduced their stake in the company, which could be perceived negatively by investors.

Risks

• Continued selling pressure from insiders could negatively impact the stock price.

Industry Context

Insider transactions are closely monitored in the biotech industry as they can provide insights into management's view of the company's prospects. However, sales do not always indicate a negative outlook, as insiders may sell for various personal financial reasons.

Stakeholder Impact

• Shareholders may react to the news of insider selling, potentially leading to price volatility.

Key Dates